Clinical Briefings™: Evaluating Current Treatments and Multidisciplinary Approaches to Amyotrophic Lateral Sclerosis Care

Released On
December 23, 2019

Expires On
December 23, 2020

Media Type

Completion Time
60 minutes

Hospitalist, Neurology, Primary Care

Amyotrophic Lateral Sclerosis

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


Supported by an educational grant from Mitsubishi Tanabe Pharma America, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward neurologists, internists, and other healthcare professionals involved in the treatment of patients with ALS, such as primary care physicians, nurse practitioners, and physician assistants.

Program Overview

This continuing medical education (CME) online activity, Clinical Briefings™: Evaluating Current Treatments and Multidisciplinary Approaches to Amyotrophic Lateral Sclerosis Care, features text content complemented by audio commentary from Richard S. Bedlack Jr, MD, PhD, MS, a neurologist and an expert in treating patients with amyotrophic lateral sclerosis (ALS). This activity provides an overview of the complex disease pathophysiology and etiology of ALS, discusses the clinical presentation and diagnostic evaluation in this setting, emphasizes the importance of multidisciplinary care, and evaluates the efficacy and safety of therapies recommended for both symptom control and agents that may modify the disease course of ALS.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Review the complex pathophysiology and etiology of ALS and the challenges of accurate and timely diagnosis
  • Develop multidisciplinary strategies targeting the multisystemic disease burden for patients with ALS
  • Evaluate the efficacy and safety of disease-targeting and symptom-based therapies for patients with ALS


Richard S. Bedlack Jr, MD, PhD, MS

Professor, Department of Neurology
Director, Duke ALS Clinic
Duke University
Durham, NC

Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Richard S. Bedlack Jr, MD, PhD, MS

  • Grant/Research Support: ALS Association, Motor Neurone Disease Association, Cytokinetics, Ultragenyx, Orion
  • Consultant: ALS Association, Biogen, Biohaven Pharmaceuticals, BrainStorm, Cytokinetics, ITF Pharma, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma, New Biotic, Woolsey Pharmaceuticals.

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Method of Participation

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Audio” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.